Swisse-High Strength Cranberry 30 Capsules

Swisse
Swisse-High Strength Cranberry 30 Capsules
Shop all Other

Product Description

Swisse Ultiboost High Strength Cranberry is a premium quality, one-a-day formula to help support urinary tract health.

Clinically Tested: Contains PACran(r), a clinically trialled high-potency cranberry that is a unique powdered form of the whole cranberry fruit to help support urinary tract health.

Symptomatic Relief: PACran(r) may help provide symptomatic relief from the discomfort associated with recurrent cystitis such as itching, burning and frequent urination.

Antioxidant Support: Cranberries are high in antioxidants, which help protect against potential free radical damage. Cranberries possess anti-adhesion qualities, which help reduce the adhesion of bacteria to the urinary tract.

Swisse Ultiboost High Strength Cranberry has been formulated based on scientific evidence to provide a high strength dose of cranberry in a convenient one-a-day dose.

Active Ingredients

Cranberry (Vaccinium macrocarpon) powder equiv. fresh fruit 25 g)

** No added gluten, lactose, egg, yeast, preservatives and artificial flavours.

Directions For Use

One capsule daily, during or immediately after a meal, or as directed by a healthcare professional.

Warning

Always read the label.

Use only as directed.

If pain or irritation persists for more than 48 hours - consult your doctor. The presence of blood in the urine warrants immediate medical attention.

About Swisse

Swisse is an Australian success story. It all began with founder Kevin Ring in a humble Melbourne warehouse in 1969. From the outset, our mission was embedded in the Swisse DNA - a dream to make people all over the world healthier and happier. Today, the Swisse product range stretches from top selling men's and women's multivitamins and dietary supplements, to sports nutrition, skincare and functional foods. Swisse products are currently available in Australia, New Zealand, China, Singapore, the UK, Italy and the Netherlands, with plans to launch in up to 30 countries in the next five years.